PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 228 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $83,000 | -8.8% | 1,561 | 0.0% | 0.02% | -8.7% |
| Q2 2022 | $91,000 | -48.3% | 1,561 | -32.7% | 0.02% | -42.5% |
| Q1 2022 | $176,000 | +633.3% | 2,318 | +489.8% | 0.04% | +566.7% |
| Q4 2021 | $24,000 | +9.1% | 393 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $22,000 | -59.3% | 393 | -56.0% | 0.01% | -57.1% |
| Q2 2021 | $54,000 | -81.2% | 893 | -78.2% | 0.01% | -83.1% |
| Q1 2021 | $287,000 | +825.8% | 4,093 | +694.8% | 0.08% | +730.0% |
| Q4 2020 | $31,000 | -24.4% | 515 | -23.7% | 0.01% | +25.0% |
| Q3 2020 | $41,000 | -47.4% | 675 | -54.6% | 0.01% | -72.4% |
| Q2 2020 | $78,000 | +212.0% | 1,487 | +102.3% | 0.03% | +141.7% |
| Q1 2020 | $25,000 | -24.2% | 735 | 0.0% | 0.01% | -7.7% |
| Q4 2019 | $33,000 | +17.9% | 735 | 0.0% | 0.01% | +30.0% |
| Q3 2019 | $28,000 | +3.7% | 735 | +20.3% | 0.01% | -9.1% |
| Q2 2019 | $27,000 | +17.4% | 611 | 0.0% | 0.01% | +10.0% |
| Q1 2019 | $23,000 | – | 611 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tamarack Advisers, LP | 360,000 | $21,845,000 | 6.19% |
| Gagnon Advisors, LLC | 213,217 | $12,938,000 | 4.92% |
| GAGNON SECURITIES LLC | 499,333 | $30,300,000 | 4.30% |
| Spyglass Capital Management LLC | 2,117,673 | $128,500,000 | 2.86% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 646,530 | $39,231,000 | 2.30% |
| Paulson & Co. | 1,273,161 | $77,255,000 | 1.85% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 212,112 | $12,871,000 | 1.44% |
| Tygh Capital Management, Inc. | 152,332 | $9,244,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,147,000 | $69,600,000 | 1.24% |
| Rock Springs Capital Management LP | 1,025,000 | $62,197,000 | 1.23% |